COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Fundamental Analysis
NASDAQ:COLL - Nasdaq - US19459J1043 - Common Stock - Currency: USD
COLL gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While COLL belongs to the best of the industry regarding profitability, there are concerns on its financial health. COLL has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
COLL had positive earnings in the past year.
In the past year COLL had a positive cash flow from operations.
In multiple years COLL reported negative net income over the last 5 years.
COLL had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
COLL's Return On Assets of 5.42% is amongst the best of the industry. COLL outperforms 90.10% of its industry peers.
The Return On Equity of COLL (37.82%) is better than 96.88% of its industry peers.
COLL's Return On Invested Capital of 10.46% is amongst the best of the industry. COLL outperforms 88.02% of its industry peers.
COLL had an Average Return On Invested Capital over the past 3 years of 8.70%. This is significantly below the industry average of 43.55%.
The last Return On Invested Capital (10.46%) for COLL is above the 3 year average (8.70%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.42% | ||
| ROE | 37.82% | ||
| ROIC | 10.46% |
ROA(3y)4.14%
ROA(5y)1.83%
ROE(3y)15.68%
ROE(5y)7.1%
ROIC(3y)8.7%
ROIC(5y)N/A
1.3 Margins
COLL's Profit Margin of 14.78% is amongst the best of the industry. COLL outperforms 90.10% of its industry peers.
COLL's Profit Margin has been stable in the last couple of years.
COLL has a better Operating Margin (32.29%) than 95.31% of its industry peers.
In the last couple of years the Operating Margin of COLL has grown nicely.
Looking at the Gross Margin, with a value of 62.36%, COLL is in the better half of the industry, outperforming 69.79% of the companies in the same industry.
In the last couple of years the Gross Margin of COLL has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.29% | ||
| PM (TTM) | 14.78% | ||
| GM | 62.36% |
OM growth 3Y19.53%
OM growth 5YN/A
PM growth 3Y-0.58%
PM growth 5YN/A
GM growth 3Y-0.26%
GM growth 5Y7.07%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so COLL is still creating some value.
COLL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of 0.98, we must say that COLL is in the distress zone and has some risk of bankruptcy.
COLL has a Altman-Z score of 0.98. This is comparable to the rest of the industry: COLL outperforms 58.85% of its industry peers.
The Debt to FCF ratio of COLL is 4.51, which is a neutral value as it means it would take COLL, 4.51 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of COLL (4.51) is better than 87.50% of its industry peers.
A Debt/Equity ratio of 3.43 is on the high side and indicates that COLL has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 3.43, COLL is doing worse than 83.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.43 | ||
| Debt/FCF | 4.51 | ||
| Altman-Z | 0.98 |
ROIC/WACC1.07
WACC9.75%
2.3 Liquidity
A Current Ratio of 0.97 indicates that COLL may have some problems paying its short term obligations.
COLL has a Current ratio of 0.97. This is amonst the worse of the industry: COLL underperforms 84.90% of its industry peers.
A Quick Ratio of 0.88 indicates that COLL may have some problems paying its short term obligations.
COLL has a Quick ratio of 0.88. This is amonst the worse of the industry: COLL underperforms 81.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.97 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
COLL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 446.61%, which is quite impressive.
The Earnings Per Share has been growing by 154.78% on average over the past years. This is a very strong growth
EPS 1Y (TTM)446.61%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%115.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.51%
3.2 Future
Based on estimates for the next years, COLL will show a small growth in Earnings Per Share. The EPS will grow by 5.11% on average per year.
Based on estimates for the next years, COLL will show a small growth in Revenue. The Revenue will grow by 2.92% on average per year.
EPS Next Y3.27%
EPS Next 2Y6.33%
EPS Next 3Y-3.06%
EPS Next 5Y5.11%
Revenue Next Year17.49%
Revenue Next 2Y10.19%
Revenue Next 3Y4.35%
Revenue Next 5Y2.92%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 4.48 indicates a rather cheap valuation of COLL.
Based on the Price/Earnings ratio, COLL is valued cheaper than 97.92% of the companies in the same industry.
COLL's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 29.35.
Based on the Price/Forward Earnings ratio of 4.34, the valuation of COLL can be described as very cheap.
Based on the Price/Forward Earnings ratio, COLL is valued cheaper than 96.35% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.10, COLL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.48 | ||
| Fwd PE | 4.34 |
4.2 Price Multiples
COLL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. COLL is cheaper than 96.35% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, COLL is valued cheaply inside the industry as 97.92% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.73 | ||
| EV/EBITDA | 4.61 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of COLL may justify a higher PE ratio.
A cheap valuation may be justified as COLL's earnings are expected to decrease with -3.06% in the coming years.
PEG (NY)1.37
PEG (5Y)N/A
EPS Next 2Y6.33%
EPS Next 3Y-3.06%
5. Dividend
5.1 Amount
No dividends for COLL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
28.91
-0.89 (-2.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners117.57%
Inst Owner Change-3.89%
Ins Owners1.67%
Ins Owner Change3.71%
Market Cap910.38M
Analysts81.82
Price Target43.66 (51.02%)
Short Float %16.5%
Short Ratio12.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.03%
Min EPS beat(2)-0.88%
Max EPS beat(2)6.95%
EPS beat(4)3
Avg EPS beat(4)19.84%
Min EPS beat(4)-0.88%
Max EPS beat(4)51.47%
EPS beat(8)5
Avg EPS beat(8)-25.67%
EPS beat(12)6
Avg EPS beat(12)-31.34%
EPS beat(16)6
Avg EPS beat(16)-34.48%
Revenue beat(2)1
Avg Revenue beat(2)-0.33%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)0.39%
Revenue beat(4)1
Avg Revenue beat(4)-1.15%
Min Revenue beat(4)-3.25%
Max Revenue beat(4)0.39%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-5.91%
Revenue beat(16)6
Avg Revenue beat(16)-5.15%
PT rev (1m)-0.47%
PT rev (3m)1.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.16%
EPS NY rev (1m)0%
EPS NY rev (3m)0.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.48 | ||
| Fwd PE | 4.34 | ||
| P/S | 1.52 | ||
| P/FCF | 4.73 | ||
| P/OCF | 4.7 | ||
| P/B | 3.89 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.61 |
EPS(TTM)6.45
EY22.31%
EPS(NY)6.66
Fwd EY23.04%
FCF(TTM)6.11
FCFY21.14%
OCF(TTM)6.15
OCFY21.28%
SpS19.03
BVpS7.44
TBVpS-27.26
PEG (NY)1.37
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.42% | ||
| ROE | 37.82% | ||
| ROCE | 16.46% | ||
| ROIC | 10.46% | ||
| ROICexc | 11.65% | ||
| ROICexgc | N/A | ||
| OM | 32.29% | ||
| PM (TTM) | 14.78% | ||
| GM | 62.36% | ||
| FCFM | 32.11% |
ROA(3y)4.14%
ROA(5y)1.83%
ROE(3y)15.68%
ROE(5y)7.1%
ROIC(3y)8.7%
ROIC(5y)N/A
ROICexc(3y)14.87%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.69%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y24.23%
ROICexc growth 5YN/A
OM growth 3Y19.53%
OM growth 5YN/A
PM growth 3Y-0.58%
PM growth 5YN/A
GM growth 3Y-0.26%
GM growth 5Y7.07%
F-Score6
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.43 | ||
| Debt/FCF | 4.51 | ||
| Debt/EBITDA | 2.35 | ||
| Cap/Depr | 0.84% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 3.08 | ||
| Cash Conversion | 56.69% | ||
| Profit Quality | 217.22% | ||
| Current Ratio | 0.97 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 0.98 |
F-Score6
WACC9.75%
ROIC/WACC1.07
Cap/Depr(3y)143.52%
Cap/Depr(5y)215.73%
Cap/Sales(3y)41.48%
Cap/Sales(5y)49.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)446.61%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%115.85%
EPS Next Y3.27%
EPS Next 2Y6.33%
EPS Next 3Y-3.06%
EPS Next 5Y5.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.51%
Revenue Next Year17.49%
Revenue Next 2Y10.19%
Revenue Next 3Y4.35%
Revenue Next 5Y2.92%
EBIT growth 1Y48.37%
EBIT growth 3Y46.16%
EBIT growth 5YN/A
EBIT Next Year153.21%
EBIT Next 3Y42.12%
EBIT Next 5Y17.89%
FCF growth 1Y140.16%
FCF growth 3YN/A
FCF growth 5Y13.6%
OCF growth 1Y105.83%
OCF growth 3Y43.03%
OCF growth 5Y10.16%